A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Trial Profile

A Phase 1, Open-label, Dose Escalation Study of Intravenous PRX004 in Subjects With Amyloid Transthyretin (ATTR) Amyloidosis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 08 May 2018

At a glance

  • Drugs PRX 004 (Primary)
  • Indications Amyloidosis
  • Focus Adverse reactions; First in man
  • Sponsors Prothena
  • Most Recent Events

    • 08 May 2018 According to a Prothena media release, the company initiated the study in the second quarter of 2018 and preliminary data from this study is expected in 2019.
    • 08 May 2018 Status changed from not yet recruiting to recruiting, according to a Prothena media release.
    • 16 Nov 2017 According to a Prothena media release, this study is expected to initiate by mid-2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top